DefinitionThis section has been translated automatically.
Abatacept is a recombinant fusion protein consisting of the extracellular domain of human cytotoxic T lymphocyte antigen-4 (CTLA-4) and a modified Fc portion of human immunoglobulin G1 (IgG1).
Pharmacodynamics (Effect)This section has been translated automatically.
Abatacept binds to CD80 and CD86 on the surface of antigen-presenting cells and thereby selectively modulates the costimulatory signaling pathway. In doing so, Abatacept impairs the response of naïve T lymphocytes more than that of memory T cells. According to studies, levels of inflammatory markers and interleukin-2 (IL-2) receptor as a marker of T-cell activation decreased in a dose-dependent manner.
Abatacept reduces the antigen-specific production of TNFα, interferon-γ and interleukin-2 by T lymphocytes and thus alters the inflammatory process.
You might also be interested in
IndicationThis section has been translated automatically.
Abatacept is approved in combination with methotrexate in adults for the treatment of rheumatoid arthritis. It is indicated for the: treatment of moderate to severe rheumatoid arthritis when previous treatment with at least one modifying antirheumatic drug (including methotrexate or a TNF-α inhibitor) has been unsatisfactory; and treatment of highly active and progressive rheumatoid arthritis not previously treated with methotrexate.
Alone or in combination with methotrexate, abatacept is also indicated in adults for the treatment of active psoriatic arthritis when previous treatment with DMARDs, including methotrexate, has been unsuccessful. Furthermore, the agent can be used in combination with methotrexate for the treatment of polyarticular juvenile idiopathic arthritis in children 6 years of age and older and adolescents. Abatacept is intended for the treatment of moderate to severe active forms of polyarticular juvenile idiopathic arthritis that do not respond adequately to other DMARDs, including at least one TNF inhibitor.
Off-label: The outcome of an open-label study evaluating the efficacy of Abatacept in alopecia areata remains to be seen (Mackay-Wiggan J et al. 2021).
Limited indicationThis section has been translated automatically.
Dosage and method of useThis section has been translated automatically.
- < 60 kg KG: 500 mg i.v. as a 30-minute i.v. infusion.
- 60-100 kg KG: 750 mg i.v. as a 30-minute i.v. infusion.
- > 100 kg KG 1 g i.v. as 30-minute i.v. infusion.
Undesirable effectsThis section has been translated automatically.
Side effects of Abatacept according to their frequency:
- Upper respiratory tract infections.
- Lower respiratory tract infections
- Urinary tract infections
- Herpes infections
- Abdominal pain, nausea, vomiting, diarrhea
- ulceration of the mouth
- aphtous stomatitis
- liver dysfunction, increased transaminases
- fatigue, asthenia.
- Dental infections
- musculoskeletal infections
- Ear infections
- thrombocytopenia, leukopenia
- depression, anxiety
- Sleep disorders
- conjunctivitis, dry eyes
- reduced visual acuity
- palpitations, tachycardia, bradycardia
- hot flushes, flush
- worsening of chronic obstructive pulmonary disease, bronchospasm
- increased tendency to bruising
- arthralgia, pain in the limbs
- amenorrhea, menorrhagia
- flu-like symptoms
- weight gain.
- gastrointestinal infections
- Pelvic inflammatory disease
- malignant neoplasms of the lung
Integumentary side effects:
Very common: exanthema
Occasional: abscesses of the skin, dry skin, pruritus, urticaria, psoriasis, acne, erythema, (viral) papillomas of the skin
Increased tumor risk: Compared to other DMARDs, the use of Abatacept was associated with an increased incidence of overall cancer. There was a significantly increased incidence of non-melanoma skin cancer (mainly basal cell carcinoma). There was no significant difference for other types of carcinoma (Montastruc F et al. 2019). However, this statement is not unchallenged (Simon TA et al.2019).
The combination with a biologic, especially TNF alfa blockers, e.g. etanercept, adalimumab, infliximab, is particularly unfavorable with regard to the susceptibility to infectivity and is therefore not recommended.
InteractionsThis section has been translated automatically.
Combination with other drugs: Methotrexate, NSAIDs and corticosteroids showed no effect on abatacept clearance in pharmacokinetic studies. There are no major safety concerns with the use of abatacept in combination with sulfasalazine, hydroxychloroquine, or leflunomide.
Combination with other drugs affecting the immune system: Con comitant use of Abatacept and immunosuppressive or immunomodulatory biologics could potentiate the effect of Abatacept on the immune system. Insufficient data are available to assess the safety and efficacy of Abatacept in combination with anakinra or rituximab.
Vaccinations: Due to lack of data on safety, live vaccines should not be given concomitantly with Abatacept or within 3 months of discontinuation. The efficacy of immunizations may be attenuated. Some clinical data suggest that while Abatacept may attenuate the effectiveness of the immune response, the ability to mount a positive immune response is not significantly inhibited.
Combination with TNF antagonists: There is limited experience in the use of abatacept in combination with TNF antagonists. Concurrent treatment with Abatacept and a TNF antagonist is not recommended (risk of serious infections).
ContraindicationThis section has been translated automatically.
hypersensitivity to the active substance
severe infections (sepsis, severe opportunistic infections).
PreparationsThis section has been translated automatically.
Orencia® (Bristol-Myers Squibb)
Note(s)This section has been translated automatically.
There is limited experience in the use of abatacept in combination with TNF antagonists. Patients treated concomitantly with Abatacept and TNF antagonists experienced more infections (including more serious infections) than patients treated with TNF antagonists alone. Concurrent treatment with Abatacept and a TNF antagonist is not recommended.
LiteratureThis section has been translated automatically.
- Blair HA et al.(2017) Abatacept: A Review in Rheumatoid Arthritis. Drugs 77:1221-1233.
- Furst DE, Breedveld FC et al. (2006) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.Ann Rheum Dis 65(Suppl 3): iii2-15.
- Kuek A, Hazleman BL, Ostör AJ (2007) Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J 83:251-260
- Montastruc F et al (2019) Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study. Rheumatology (Oxford) 58:683-691.
- Mackay-Wiggan J et al.(2021) An open-label study evaluating the efficacy of abatacept in alopecia areata. J Am Acad Dermatol 84: 841-844.
- Renert-Yuval Y et al.(2017) The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm. Adv Ther 34:1594-1609.
- Simon TA et al.(2019) Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study. Arthritis Res Ther 21:228.